Last updated: June 14, 2026
Litigation summary for ADAMAS PHARMA, LLC v. SANDOZ INC., 3:18-cv-09032: what’s at issue, what the case history shows, and how it affects generic launch risk
Executive summary
ADAMAS PHARMA, LLC sued Sandoz in the US District Court for the District of New Jersey in 2018 under the Hatch-Waxman framework (likely a Paragraph IV patent infringement claim tied to Sandoz’s ANDA). The case is docketed as 3:18-cv-09032 and centers on whether Sandoz’s proposed generic product infringes one or more ADAMAS-listed Orange Book patents and whether those patents are invalid or unenforceable. The litigation’s practical impact is that it sets the time window, licensing pressure points, and entry barriers for Sandoz’s generic exposure during the relevant regulatory exclusivity and patent-expiration period.
No further case-specific details (asserted patents, court rulings, claim construction outcomes, settlement terms, and final disposition) can be produced from the information provided.
What patents were asserted in ADAMAS PHARMA v. SANDOZ 3:18-cv-09032?
Featured snippet: The specific asserted patent numbers and claims cannot be stated from the provided docket reference alone.
Which Orange Book patents typically drive these ADAMAS v. Sandoz actions
Featured snippet: Hatch-Waxman suits tied to an ANDA usually assert one or more Orange Book-listed patents in at least one category:
- composition-of-matter
- formulations
- method-of-use
- manufacturing process
Patent categories and infringement theories likely at issue
Typical theories in this posture include:
- infringement by the ANDA product (literal or equivalents)
- invalidity arguments based on anticipation/obviousness, lack of enablement, indefiniteness, or written description
- unenforceability challenges (inequitable conduct or other defenses), if raised
What procedural milestones occurred in 3:18-cv-09032?
Featured snippet: The docket milestones cannot be mapped without access to the case record.
Common milestone types in ADAMAS-style Hatch-Waxman filings
- complaint served after ANDA paragraph IV notice
- case management and scheduling order
- infringement/validity expert deadlines
- Markman or claim construction (if the court orders it)
- summary judgment, if either side seeks early resolution
- trial (if not settled or resolved by summary judgment)
- post-judgment motions and appeals
How did the court rule on infringement and validity?
Featured snippet: The outcome on infringement and validity cannot be stated from the provided information.
If the court grants judgment of non-infringement
Practical impact is generally:
- design-around viability increases
- generic entry risk decreases
- downstream settlements may unwind
If the court grants judgment of infringement or invalidity is rejected
Practical impact is generally:
- stay of FDA approval persists (to the extent applicable)
- generic launch is delayed pending appeal or redesign
- licensing pressure rises for any remaining authorized generic or co-marketing pathways
Did the case settle, and what did the settlement require?
Featured snippet: Settlement terms and whether a consent judgment entered cannot be stated from the provided docket reference alone.
Typical settlement structures in Hatch-Waxman
- covenant not to sue covering specific FDA-approved strengths/forms
- negotiated “launch at risk” dates
- delayed entry contingent on patent expiration
- stipulations on court-ordered findings
- payment or other consideration (if alleged in later enforcement actions)
Settlement relevance to investors and licensing teams
- determines the actual economic entry date
- informs whether follow-on patents can still block launch
- clarifies whether design changes avoid infringement
What does 3:18-cv-09032 mean for generic entry risk?
Featured snippet: Entry risk is tied to the remaining unexpired patents and the procedural posture, but the case’s disposition is not provided.
Entry risk framework professionals use
- Regulatory: any Orange Book-listed patents still in effect
- Litigation: stay duration, final judgment status, and appeal posture
- Patent estate: whether there are additional “continuation” or follow-on patents
- Product: whether generic design changes are sufficient to avoid infringement
Which companies and drug product are implicated in ADAMAS v. SANDOZ (3:18-cv-09032)?
Featured snippet: The case identifies ADAMAS PHARMA, LLC as plaintiff and SANDOZ INC. as defendant, but the specific drug product is not stated in the provided prompt.
Why the “drug identity” matters for litigation analysis
- which Orange Book patents were listed for that product
- whether the asserted patents are formulation, composition, or method-of-use
- which FDA application and ANDA approval status is implicated
- whether the case involves 505(b)(2) versus ANDA-only alignment
How strong is the patent estate reflected by this lawsuit?
Featured snippet: The strength profile cannot be computed without the asserted-patent list and case outcome.
How litigated patent strength typically gets evaluated
- claim breadth and remaining scope
- proximity to a claim of composition versus method-of-use
- litigation history of the same patents (prior invalidity outcomes)
- enforceability posture (inequitable conduct rulings)
- whether claim construction narrows infringement exposure
How does this case compare with other ADAMAS generic challenges to Sandoz and peers?
Featured snippet: Direct comparisons require asserted-patent and outcome details from 3:18-cv-09032 and parallel cases.
Comparison dimensions used in competitive patent landscaping
- same active ingredient, different ANDA filer
- shared asserted patent(s) versus different patent subsets
- outcomes by court, judge, and claim construction
- settlement-versus-trial resolution patterns
Key Takeaways
- ADAMAS PHARMA, LLC brought a Hatch-Waxman patent dispute against SANDOZ INC. in 2018 under case number 3:18-cv-09032.
- The litigation’s business effect is to define the time and legal pathway for Sandoz’s proposed generic entry.
- A complete, accurate analysis of asserted patents, rulings, settlement terms, and resulting entry/launch timelines cannot be provided from the docket identifier alone.
FAQs
- What does “3:18-cv-09032” indicate in a Hatch-Waxman context?
- Does the docket number alone identify the asserted Orange Book patents?
- How do Paragraph IV cases typically affect FDA approval timelines?
- What outcome elements determine whether generics can launch “at risk”?
- How do settlement agreements in Hatch-Waxman cases influence follow-on patent challenges?
References
- United States District Court, District of New Jersey. ADAMAS PHARMA, LLC v. SANDOZ INC., Case No. 3:18-cv-09032 (docket reference provided).
